Ibogaine side effects and contraindications

Evidence level: C Emerging evidence — observational studies and case series, no randomised controlled trials yet. We say so wherever it matters.

Ibogaine’s effects fall into two categories that should never be blurred together.

The first are expected and manageable: nausea, unsteadiness, exhaustion, disrupted sleep. They are unpleasant, they are anticipated by any competent clinical team, and they pass.

The second is cardiac, and it is the reason ibogaine must only ever be given after medical screening and with continuous monitoring. It is not common in properly screened patients — and it is what makes unsupervised use genuinely dangerous.

This page separates the two honestly, and sets out the specific conditions that rule treatment out.

Common effects during treatment

These are reported by most patients and are treated as part of the procedure rather than as complications.

Nausea and vomiting. The most common physical effect, and predictable enough that clinics pre-empt it: in the published Brazilian protocol, patients receive an anti-nausea medication (domperidone 20 mg) 30–45 minutes before dosing, and are asked to arrive fasted so that there is little in the stomach to bring up.

Impaired coordination. Balance and coordination are significantly affected during the acute phase. This is why patients remain in bed in a private room and require assistance to move — attempting to walk unaided is a fall risk, not a test of willpower.

Sensitivity to light and sound. Sessions are conducted in quiet, low-stimulus conditions for this reason.

Inability to sleep during the session. The acute phase, lasting around ten hours, is not a sleep state — patients are awake and internally occupied throughout.

After-effects in the following days

The acute phase ends; the compound does not leave immediately. Noribogaine, ibogaine’s long-acting metabolite, remains active for days, and patients typically report:

Deep fatigue. Frequently described as the dominant feature of the first days — physically drained, with mental clarity often returning before energy does.

Insomnia. Difficulty sleeping despite exhaustion is common and can persist for several days.

An emotionally flat or subdued period. Widely reported after the intensity of the session, and generally short-lived.

Continued psychological processing. The material that surfaces during the session tends to keep surfacing afterwards. This is one reason the published protocol advises patients to avoid social activity for at least seven days after treatment, and why psychotherapy resumes in this period rather than months later.

Most people find normal energy and sleep return over several days to a couple of weeks, with considerable individual variation.

The serious risk — cardiac effects

This is the one that matters, and it deserves precision rather than euphemism.

Ibogaine slows the heart rate and prolongs the QT interval — the measure of how long the heart’s electrical system takes to reset between beats. Pharmacologically this occurs through inhibition of specific potassium channels (encoded by the hERG gene) that govern that reset.

A prolonged QT interval raises the risk of dangerous arrhythmia. In the medical literature, long-QT is the most widely accepted explanation for the serious adverse events that have been reported with ibogaine. Reviews of fatality cases have also found that many involved significant pre-existing conditions — cardiovascular disease, hypertension and others — which is precisely what pre-treatment screening exists to detect.

Two practical consequences follow.

First, this risk is largely identifiable in advance. An ECG and blood work — particularly electrolytes, which affect cardiac conduction — reveal most of the people for whom ibogaine would be unsafe. That is why responsible programmes turn a significant share of applicants away.

Second, it is why monitoring exists. Cardiac effects occur during and after the session, and continuous monitoring for 24 to 48 hours is what allows an emerging problem to be caught rather than discovered.

Is ibogaine safe? →

Drug interactions — the most underestimated danger

Interactions cause more harm in this field than the compound alone, and three deserve specific attention.

Opioids. Ibogaine increases the toxicity of opioids. This is why patients on long-acting medication such as methadone are switched to a short-acting opioid beforehand, and why treatment begins only once early withdrawal has appeared — visible withdrawal confirms that little opioid remains in circulation.

Stimulants. Cocaine and crack withdrawal slows the heart; ibogaine slows it further and prolongs the QT interval. The two effects compound. The published protocol required abstinence of at least 30 days, later extended to 60, specifically to avoid pharmacological interaction — and the research notes that cocaine’s effect on the QT interval diminishes significantly after around a week of abstinence.

Prescription medication. Any drug that affects the QT interval — including some antidepressants, antipsychotics, antibiotics and antihistamines — requires review and often adjustment well in advance. This is not something to disclose on arrival; it determines whether treatment can proceed at all.

The patient instruction sheet used in Dr. Rasmussen’s programme is blunt about this: take no medication without the physician’s explicit approval, including sleep aids, because some are incompatible with ibogaine and will cause the treatment to be postponed.

Contraindications — who cannot be treated

The published protocol from the Brazilian programme lists explicit exclusion criteria. It is a useful benchmark because it is specific rather than vague:

  • Pregnancy
  • Surgery within the previous six months
  • Uncontrolled high blood pressure
  • Uncontrolled diabetes
  • Cardiac arrhythmias
  • Renal (kidney) insufficiency
  • Hepatic (liver) insufficiency
  • Alzheimer’s disease
  • Parkinson’s disease
  • Psychiatric comorbidities, including psychosis and schizophrenia

Inclusion required the opposite: general good health confirmed by clinical testing — electrolytes, liver enzymes (AST, ALT, GGT, bilirubin), kidney function, blood sugar and full blood count — together with motivation, family support, and willingness to take part in psychotherapy before and after treatment.

Several of these are correctable rather than permanent. An electrolyte imbalance can be treated; uncontrolled blood pressure or diabetes can be brought under control. “Not now” and “not ever” are different answers, and only a physician reviewing your actual results can tell you which one applies.

Is ibogaine safe? →

The riskiest period is after treatment

This is the point most often missed, and it costs lives.

For days after the session, noribogaine remains active in the body. During exactly this period, withdrawal and craving have lifted — for many patients, for the first time in years. Tolerance has also changed.

Returning to a previous dose of any substance in that window is not simply a relapse. It is a pharmacological interaction with a compound still circulating, at a tolerance that no longer matches the dose. A meaningful proportion of deaths attributed to ibogaine involved other substances taken in this period.

If you take nothing else from this page: the days after treatment require the same care as the day of it.

What happens after ibogaine treatment →

What the published safety data shows

In the retrospective study co-authored by Dr. Rasmussen and published in the Journal of Psychopharmacology in 2014, 75 patients treated for alcohol, cannabis, cocaine and crack dependence were reviewed. The authors reported no serious adverse reactions and no fatalities.

The honest caveats: this describes one screened cohort in one hospital-based programme, it was retrospective rather than a controlled trial, and it was non-opioid — so its findings should not be transferred wholesale to opioid patients, where the interaction profile differs.

What it does demonstrate is narrower but still meaningful: with rigorous screening, a hospital setting and mandatory psychotherapy, a programme can treat 75 dependent patients without serious harm.

Ibogaine research and evidence →

Questions to ask before treatment

Ask any provider, and expect specific answers:

  1. Which blood tests do you require, and who reviews the results?
  2. Do you perform an ECG, and what QT threshold would rule me out?
  3. What is your policy on my current medication — who reviews it, and how far in advance?
  4. How long must I be abstinent from my substance before treatment, and how is that verified?
  5. What anti-nausea premedication do you use?
  6. How many hours of monitoring are included, and by whom?
  7. What conditions would cause you to decline me?

A provider unable to answer question seven has not thought seriously about the other six.

How to choose an ibogaine clinic →

Getting an honest assessment

No article can tell you whether ibogaine is safe for you — that requires a physician reviewing your medical history, current medication and test results.

Rehab Global is not a clinic, and we will not tell you that your contraindications are manageable when they are not: only the clinic’s doctors can judge that.

Ask about your options

Free and confidential. We’ll review your history, including medications and medical conditions, and reply within 24 hours.

Sources

  1. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. Journal of Psychopharmacology. 2014;28(11):993–1000. doi:10.1177/0269881114552713

Frequently asked questions

01. What are the side effects of ibogaine?
Commonly nausea, vomiting, impaired coordination, sensitivity to light and sound, and insomnia. The serious risk is cardiac — slowed heart rate and QT prolongation.
02. Does ibogaine cause nausea?
Yes, commonly. Clinics typically give anti-nausea premedication beforehand and ask patients to arrive fasted.
03. How long do ibogaine after-effects last?
Fatigue, insomnia and a flat mood are common for several days; most people return to normal within days to a couple of weeks.
04. Does ibogaine affect the heart?
Yes. It slows heart rate and prolongs the QT interval by inhibiting hERG potassium channels, which is why ECG screening and monitoring are essential.
05. Who should not take ibogaine?
Contraindications include pregnancy, recent surgery, uncontrolled hypertension or diabetes, cardiac arrhythmias, kidney or liver insufficiency, Alzheimer's, Parkinson's and psychiatric comorbidities.
06. What medications interact with ibogaine?
Opioids (whose toxicity it increases), stimulants, and any drug affecting the QT interval — including some antidepressants and antibiotics. All medication must be reviewed in advance.
07. Are there long-term side effects of ibogaine?
Long-term data is limited. In the published 75-patient study no serious adverse reactions were reported, but that is a small cohort and not a controlled trial.

This article is for information only and is not medical advice. It cannot tell you whether ibogaine is safe in your case — that requires a physician reviewing your medical history, medication and test results. Ibogaine carries a risk of serious cardiac events and must never be taken without medical screening and supervision.

Get a free, confidential assessment

Our consultation is free for you. Medical decisions are made by the clinic's doctors.